News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sanofi (France) (SAN.PA)'s Lantus Cut Blood Sugar More Than Merck & Co., Inc. (MRK)'s Januvia


6/11/2012 7:43:38 AM

Novo Nordisk and Sanofi are among the companies which have been presenting data on their investigational and already-marketed drugs at the American Diabetes Association conference in Philadelphia. First up, Novo reported results comparing degludec, its ultra-long-acting insulin, with Sanofi's Lantus (insulin glargine), the world's biggest-selling insulin product. The Phase IIIa 1,030-patient study showed that degludec significantly reduced the rate of hypoglycaemia at night in adults with type 2 diabetes.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES